North America Intranasal Drug And Vaccine Delivery Market Size & Outlook
Related Markets
North America intranasal drug and vaccine delivery market highlights
- The North America intranasal drug and vaccine delivery market generated a revenue of USD 29,356.9 million in 2023.
- The market is expected to grow at a CAGR of 6.8% from 2024 to 2030.
- In terms of segment, liquid delivery device was the largest revenue generating product in 2023.
- Liquid Delivery Device is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 29,356.9 million |
| Market revenue in 2030 | USD 46,428.0 million |
| Growth rate | 6.8% (CAGR from 2023 to 2030) |
| Largest segment | Liquid delivery device |
| Fastest growing segment | Liquid Delivery Device |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Powder delivery device, Liquid Delivery Device, Pressurized Metered Dose Inhaler |
| Key market players worldwide | GSK PLC ADR, Teva Pharmaceutical Industries Ltd, AptarGroup Inc, UCB SA, Teleflex Inc, 3M Co, OptiNose Inc, Bespak, Intersect ENT |
Other key industry trends
- In terms of revenue, North America region accounted for 44.4% of the global intranasal drug and vaccine delivery market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 22,052.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intranasal Drug And Vaccine Delivery Market Scope
Intranasal Drug And Vaccine Delivery Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Intersect ENT | View profile | 251-500 | Menlo Park, California, United States, North America | http://www.intersectent.com |
| Bespak | View profile | 501-1000 | Lynn, Norfolk, United Kingdom, Europe | http://www.bespak.com |
| OptiNose Inc | View profile | 132 | 1020 Stony Hill Road, Suite 300, Yardley, PA, United States, 19067 | https://www.optinose.com |
| Teleflex Inc | View profile | 14500 | 550 East Swedesford Road, Suite 400, Wayne, PA, United States, 19087 | https://www.teleflex.com |
| UCB SA | View profile | 9083 | Allee de la Recherche, 60, Brussels, Belgium, B-1070 | https://www.ucb.com |
| AptarGroup Inc | View profile | 13800 | 265 Exchange Drive, Suite 301, Crystal Lake, IL, United States, 60014 | https://www.aptar.com |
| GSK PLC ADR | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| 3M Co | View profile | 85000 | 3M Center, St. Paul, MN, United States, 55144 | https://www.3m.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
North America intranasal drug and vaccine delivery market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intranasal drug and vaccine delivery market will help companies and investors design strategic landscapes.
Liquid delivery device was the largest segment with a revenue share of 43.36% in 2023. Horizon Databook has segmented the North America intranasal drug and vaccine delivery market based on powder delivery device, liquid delivery device, pressurized metered dose inhaler covering the revenue growth of each sub-segment from 2018 to 2030.
North America held the largest revenue share as it has a highly regulated and developed healthcare infrastructure. The rising collective efforts by key players to improve their product portfolio and ensure high-quality standards are expected to boost the adoption of intranasal drug delivery across this region. In March 2019, the U.S. FDA approved Aptar Pharma’s Bidose nasal spray device to treat depression.
In addition, being a developed economy with high disposable income, people have the option to choose from various available advanced treatments. Majority of the population in this region has health insurance and access to healthcare services. The region is expected to maintain its dominance during the forecast period owing to increasing demand for advanced nasal drug delivery systems.
Reasons to subscribe to North America intranasal drug and vaccine delivery market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America intranasal drug and vaccine delivery market databook
-
Our clientele includes a mix of intranasal drug and vaccine delivery market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America intranasal drug and vaccine delivery market , including forecasts for subscribers. This continent databook contains high-level insights into North America intranasal drug and vaccine delivery market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America intranasal drug and vaccine delivery market size, by country, 2018-2030 (US$M)
North America Intranasal Drug And Vaccine Delivery Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
